Back to search

University of Minnesota

Exploring Novel Viro-Immunotherapies Against Pancreatic Ductal Adenocarcinoma Using “Armed” Oncolytic Adenoviruses and Chimeric Antigen Receptor T-cells

Abstract

dc:description.abstract

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related mortalities and is projected to become second by 2030. Two primary features make PDAC refractory to current therapeutics: 1.) the highly immunosuppressive tumor microenvironment (TME), which suppresses activity of anti-tumor immune cells and other therapeutics, and 2.) desmoplasia, which creates a fibrotic physical barrier for infiltration of anti-tumor immune cells and therapeutics. The goal of this project is to develop novel viro-immunotherapies against PDAC that target the immunosuppressive TME and desmoplasia by utilizing “armed” oncolytic adenoviruses (OAds) and chimeric antigen receptor (CAR) T-cells. Four transgenes were selected to enhance the efficacy of the viro-immunotherapy: i.) the extracellular domain of transforming growth factor beta receptor 2 fused to fragment crystallizable antibody domain (sTGFβRII-Fc), ii.) interleukin 7 (IL7), iii.) interferon gamma (IFNγ), and iv.) the extracellular domain of T-cell immunoglobulin and mucin-domain containing 3 fused to fragment crystallizable antibody domain (sTIM3-Fc). “Armed” replication-deficient adenovirus (Ad) constructs were first generated and tested as a monotherapy to isolate transgene function from oncolytic activity to identify the transgenes that elicit the greatest anti-tumor effects. Using syngeneic mouse models, each Ad construct significantly inhibited tumor growth, enhanced anti-tumor immune cell infiltration, and altered the TME in a favorable manner. Additionally, three transgenes decreased fibrosis. When the top two transgenes (IFNγ and hsTGFβRII-Fc) were combined into a single Ad vector, the anti-tumor effects were even greater, and significant abscopal effects were observed. When testing the combination of an “armed” OAd expressing IFNγ and sTGFβRII-Fc with B7 Homology 3(B7H3)-targeted CAR T-cells (B7H3-CAR T-cells), we saw significant killing effects both in vitro and in vivo compared to all other treatments. Additionally, our xenograft mouse model showed the combination treatment enhanced cellular immunity within tumors. Overall, the findings in this study have broad implications in the field of pancreatic cancer by shedding light on how the TME can be manipulated to enhance anti-tumor effects to aid in the development of more efficient therapeutics against PDAC.

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Roach, Brett

Subjects

dc:subject × 6

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*
Dc Identifier Citation
Roach, Brett. (2026). Exploring Novel Viro-Immunotherapies Against Pancreatic Ductal Adenocarcinoma Using “Armed” Oncolytic Adenoviruses and Chimeric Antigen Receptor T-cells. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/282397.

Chain of custody

source
Harvested from
University of Minnesota
Base URL
conservancy.umn.edu/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Roach, Brett. Exploring Novel Viro-Immunotherapies Against Pancreatic Ductal Adenocarcinoma Using “Armed” Oncolytic Adenoviruses and Chimeric Antigen Receptor T-cells. 2026. https://hdl.handle.net/11299/282397